BLB-201 / BayLink Biosciences, Asieris - LARVOL DELTA

GSPT1 degrader antibody conjugate, BLB-201, for the treatment of high-risk acute myeloid leukemia (AACR 2026) - "In vivo, BLB-201 exhibited excellent synergy at low doses (0.1-0.3mg/kg) with clinical anti-AML agents (venetoclax, azacitidine and quizartinib) in systemic MV-4-11 and MOLM-13 models...We did not observe any effects of BLB-201 on normal erythroid, megakaryocytic and myeloid cell differentiation from CD34+ hematopoietic stem cells in vitro, while the CD33-targeted antibody drug conjugate, gemtuzumab ozogamacin, was highly toxic in these assays. BLB-201 DAC allows selective targeting of CD123-positive AML blasts and leukemia stem cells, minimizing direct exposure of GSPT1 degrader to healthy tissues. This unique mechanism of action may improve response rates when combined with existing targeted therapies for AML patients with high-risk or relapsed/refractory disease."

Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • CD123 • CD33 • CD34 • FLT3 • GSPT1 • IL3RA • PTPRC • TP53